Oppenheimer Asset Management Inc. Raises Holdings in Immunocore Holdings plc (NASDAQ:IMCR)

Oppenheimer Asset Management Inc. grew its position in Immunocore Holdings plc (NASDAQ:IMCRFree Report) by 26.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,491 shares of the company’s stock after purchasing an additional 1,572 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Immunocore were worth $389,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its holdings in shares of Immunocore by 103.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 836 shares of the company’s stock valued at $43,000 after purchasing an additional 426 shares during the period. Parallel Advisors LLC boosted its position in Immunocore by 10,828.6% during the second quarter. Parallel Advisors LLC now owns 765 shares of the company’s stock worth $46,000 after purchasing an additional 758 shares in the last quarter. Wells Fargo & Company MN boosted its position in Immunocore by 89.7% during the fourth quarter. Wells Fargo & Company MN now owns 827 shares of the company’s stock worth $47,000 after purchasing an additional 391 shares in the last quarter. IFP Advisors Inc boosted its position in Immunocore by 1,703.0% during the second quarter. IFP Advisors Inc now owns 1,803 shares of the company’s stock worth $78,000 after purchasing an additional 1,703 shares in the last quarter. Finally, Royal Bank of Canada purchased a new position in Immunocore during the first quarter worth approximately $79,000. 73.45% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on IMCR shares. Cantor Fitzgerald initiated coverage on Immunocore in a research report on Thursday, November 2nd. They issued an “overweight” rating on the stock. JPMorgan Chase & Co. reissued an “overweight” rating and set a $60.00 target price on shares of Immunocore in a research note on Monday, November 20th. Finally, Robert W. Baird assumed coverage on Immunocore in a research note on Tuesday, October 31st. They set an “outperform” rating and a $84.00 target price for the company. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $74.17.

Get Our Latest Research Report on Immunocore

Insider Activity

In other news, insider Leger Tina Amber St sold 4,375 shares of the business’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $69.89, for a total value of $305,768.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 5.70% of the company’s stock.

Immunocore Trading Down 0.4 %

NASDAQ:IMCR opened at $74.61 on Friday. The firm has a market cap of $3.65 billion, a PE ratio of -53.68 and a beta of 0.97. The stock has a fifty day moving average price of $67.80 and a 200 day moving average price of $58.20. Immunocore Holdings plc has a 12-month low of $42.21 and a 12-month high of $76.98. The company has a current ratio of 4.26, a quick ratio of 4.24 and a debt-to-equity ratio of 0.23.

Immunocore (NASDAQ:IMCRGet Free Report) last announced its quarterly earnings results on Tuesday, November 7th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.36. Immunocore had a negative return on equity of 19.13% and a negative net margin of 28.16%. The company had revenue of $62.89 million during the quarter, compared to the consensus estimate of $59.62 million. Sell-side analysts anticipate that Immunocore Holdings plc will post -0.95 earnings per share for the current fiscal year.

Immunocore Company Profile

(Free Report)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers.

Further Reading

Want to see what other hedge funds are holding IMCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunocore Holdings plc (NASDAQ:IMCRFree Report).

Institutional Ownership by Quarter for Immunocore (NASDAQ:IMCR)

Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.